WPC Reveals Name and Logo for its Cordless Kitchen Standard
3.9.2019 10:00:00 EEST | Business Wire | Press release
The Wireless Power Consortium (WPC) today revealed the name and logo of its wireless power standard for kitchen appliances. The Ki (pronounced “key”) Cordless Kitchen standard is represented by a logo that will distinguish standard-compliant products such as rice cookers, toasters, blenders, coffee makers, air fryers and more. The Ki Cordless Kitchen logo and mark represent safety and interoperability for wireless power for cordless kitchen devices, much like the Qi logo does for mobile devices. Live demonstrations of appliances based on the draft Ki Cordless Kitchen standard will be on display at IFA Next in Berlin this week.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190903005252/en/
With the new Ki Cordless Kitchen standard, power transmitters can be neatly hidden beneath countertops, allowing cordless appliances to be simply and intuitively placed on the counter to safely and efficiently receive up to 2.2kW of power. New induction cooktops can also incorporate the cordless kitchen technology. In addition to normal induction cooking, such cooktops can also power Ki Cordless Kitchen appliances.
To ensure safe operation, the Ki Cordless Kitchen standard prevents power from being transferred when other items, such as keys, phones, bank cards, or other objects are placed on the transmitter spot. This not only prevents items from being damaged or heated, but also allows for flexible use of kitchen space, as the same counter space can be used for food preparation, cooking, eating or even reading the newspaper. Without the hassle of the power cord, appliances can be easily stored when not in use, creating a clean, modern and uncluttered look and feel to the kitchen.
“Ultimately, the Ki Cordless Kitchen standard will change the way we interact with our kitchens,” said Hans Kablau, chair of the WPC’s Kitchen Work Group. “Not only will the standard allow everything from chopping vegetables to cooking to reading the newspaper to all take place on the same surface, it also enables a whole new category of smart cookware. These smart pans can be simply placed on a power transmitter spot and allow consumers to cook on their counters just as they would on their stove. With Ki Cordless Kitchen, consumers will experience an unprecedented convenience in their kitchens that they won’t want to live without.”
The Ki Cordless Kitchen standard works with any non-metal countertop or table surface, including marble, slate, granite, laminates, wood and many others. Enabled appliances communicate with the transmitter through near-field communication (NFC), a safe, inexpensive and pervasive technology currently used around the world in bankcards, door locks, passports, transport tickets, and more.
To drive the adoption of the Ki Cordless Kitchen standard, WPC is applying the same collaboration and commitment to quality that ushered in the widespread adoption of the Qi standard for wireless charging for smartphones and other mobile devices -- now part of 4,500 certified products in use today. Current WPC members, including prominent manufacturers, are collaborating to develop the new Ki Cordless Kitchen standard.
The draft specification of the Ki Cordless Kitchen standard is currently available for WPC members to support the continued development of the Ki Cordless Kitchen ecosystem. For more information about the new standard, visit www.wirelesspowerconsortium.com/kitchen.
IFA Next 2019
Ki Cordless Kitchen will be on display in the WPC’s booth at IFA Next. Visit Hall 26, Stand 385 to learn more about how Ki Cordless Kitchen appliances will change the kitchen experience.
About the Wireless Power Consortium
Established in 2008, the Wireless Power Consortium is an open, collaborative standards development group of more than 570 company members around the globe. WPC’s members include Apple, ASUS, Belkin, Bosch, Canon, ConvenientPower, Dell, De’Longhi, Delphi, E.G.O., Google, Haier, Huawei, IKEA, Lenovo, LG, MediaTek, Mophie, NXP, Panasonic, Philips, Samsung, Sony, TDK, Verizon Wireless and Xiaomi.
These companies -- large and small, competitors and ecosystem partners, from all parts of the industry and all parts of the globe -- collaborate for a single purpose: to design and evolve the world’s most useful, safe and efficient standards for wireless power. This includes the Qi standard (up to 15W) for mobile devices and the Ki Cordless Kitchen standard (up to 2.2kW) for kitchen appliances. For more information, visit www.wirelesspowerconsortium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190903005252/en/
Contact information
Phoebe Francis
pfrancis@golin.com
+1-972-948-1751
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
